Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | PIK3CA |
Variant | H1047K |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | PIK3CA H1047K is a hotspot mutation that lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). H1047K has been identified in the scientific literature (PMID: 27374081, PMID: 26783290, PMID: 34159748), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Dec 2024). |
Associated Drug Resistance | |
Category Variants Paths |
PIK3CA mutant PIK3CA exon21 PIK3CA H1047X PIK3CA H1047K |
Transcript | NM_006218.4 |
gDNA | chr3:g.179234296_179234298delCATinsAAG |
cDNA | c.3139_3141delCATinsAAG |
Protein | p.H1047K |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_011512894.2 | chr3:g.179234296_179234298delCATinsAAG | c.3139_3141delCATinsAAG | p.H1047K | RefSeq | GRCh38/hg38 |
NM_006218.4 | chr3:g.179234296_179234298delCATinsAAG | c.3139_3141delCATinsAAG | p.H1047K | RefSeq | GRCh38/hg38 |
NM_006218 | chr3:g.179234296_179234298delCATinsAAG | c.3139_3141delCATinsAAG | p.H1047K | RefSeq | GRCh38/hg38 |
XM_011512894 | chr3:g.179234296_179234298delCATinsAAG | c.3139_3141delCATinsAAG | p.H1047K | RefSeq | GRCh38/hg38 |
XM_006713658 | chr3:g.179234296_179234298delCATinsAAG | c.3139_3141delCATinsAAG | p.H1047K | RefSeq | GRCh38/hg38 |
NM_006218.3 | chr3:g.179234296_179234298delCATinsAAG | c.3139_3141delCATinsAAG | p.H1047K | RefSeq | GRCh38/hg38 |
XM_006713658.4 | chr3:g.179234296_179234298delCATinsAAG | c.3139_3141delCATinsAAG | p.H1047K | RefSeq | GRCh38/hg38 |
XM_006713658.5 | chr3:g.179234296_179234298delCATinsAAG | c.3139_3141delCATinsAAG | p.H1047K | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600E PIK3CA H1047K | melanoma | sensitive | Miransertib + Trametinib | Preclinical - Pdx | Actionable | In a preclinical study, a melanoma patient-derived xenograft (PDX) model harboring BRAF V600E and PIK3CA H1047K was sensitive to the combination treatment of Miransertib (ARQ092) and Mekinist (trametinib), demonstrating a greater inhibition of tumor growth when compared to either agent alone (PMID: 26469692). | 26469692 |